Article Text

PDF
Letter
Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed
  1. Yasumi Katayama1,
  2. Kouji Toyoda1,
  3. Yuumi Kusano1,
  4. Toshikuni Suda1,
  5. Shogo Adachi1,2,
  6. Itsuo Terauchi3,
  7. Shigeki Oka4,
  8. Morio Takahashi5,
  9. Masaya Tamano1
  1. 1Department of Gastroenterology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Saitama Prefecture, Japan
  2. 2Department of Gastroenterology, Uchida Hospital, Tokyo, Japan
  3. 3Department of Gastroenterology, Akiya Hospital, Satte, Saitama Prefecture, Japan
  4. 4Oka Clinic, Koshigaya, Saitama Prefecture, Japan
  5. 5Morio Clinic, Koshigaya, Saitama Prefecture, Japan
  1. Correspondence to Dr Yasumi Katayama, Department of Gastroenterology, Dokkyo Medical University Koshigaya Hospital 2-1-50 Minami-Koshigaya, Koshigaya City, Saitama Prefecture 343-8555, Japan; yasumi{at}dokkyomed.ac.jp

Statistics from Altmetric.com

We read with great interest the article by Murakami et al,1 who performed a randomised, double-blinded study of vonoprazan-based Helicobacter pylori (H. pylori) eradication therapy. They showed high success rates for vonoprazan-based first-line and second-line H. pylori treatments, with eradication rates of 92.6% and 98%, respectively. However, the study populations of second-line therapy included patients for whom both lansoprazole-based and vonoprazan-based first-line treatments failed, and those for whom vonoprazan-based first-line therapy failed numbered only 14. In terms of second-line therapy, we think that the eradication rate in patients for whom vonoprazan-based first-line therapy failed is more important.

We conducted …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.